Phreesia, Inc.

Phreesia, Inc. (PHR) Market Cap

Phreesia, Inc. has a market capitalization of $566.3M.

Financials based on reported quarter end 2026-01-31

Price: $9.32

-0.04 (-0.43%)

Market Cap: 566.31M

NYSE · time unavailable

CEO: Chaim Indig

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-07-18

Website: https://www.phreesia.com

Phreesia, Inc. (PHR) - Company Information

Market Cap: 566.31M · Sector: Healthcare

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.

Analyst Sentiment

77%
Strong Buy

Based on 25 ratings

Analyst 1Y Forecast: $30.12

Average target (based on 5 sources)

Consensus Price Target

Low

$22

Median

$25

High

$33

Average

$27

Potential Upside: 188.2%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PHREESIA INC (PHR) — Investment Overview

🧩 Business Model Overview

Phreesia Inc (PHR) is a healthcare technology company specializing in patient intake management and engagement solutions for medical providers, large healthcare organizations, and life sciences companies. The company's platform streamlines front-office administrative tasks while integrating with a variety of electronic health record (EHR) systems. Phreesia’s SaaS-based approach delivers value both to patients—by improving intake processes, appointment check-ins, and payment experiences—and to healthcare organizations, by automating workflows, facilitating compliance, and supporting revenue cycle management. The company operates a multi-sided model, generating benefits for healthcare providers and payers, as well as life sciences brands seeking patient access and engagement insights.

💰 Revenue Streams & Monetisation Model

Phreesia’s revenue is comprised of three principal streams: SaaS subscriptions, payment processing, and life sciences solutions. - **Subscription Fees:** Healthcare clients pay recurring fees for access to Phreesia’s cloud-based platform and software modules, typically under long-term multi-year agreements. Subscription pricing is generally tiered and may scale with the number of providers, locations, or patient volumes served. - **Payment Processing:** Phreesia facilitates the collection of patient payments during the intake cycle, generating transaction-based fees on payment activity processed through its platform. - **Life Sciences Solutions:** The company monetizes anonymized patient data and digital engagement opportunities, selling targeted solutions to pharmaceutical, biotech, and medical device companies seeking to reach specific patient cohorts or support clinical research initiatives. By creating a sticky ecosystem with both recurring and transaction-based revenue, Phreesia achieves a diversified monetization structure that balances high-margin SaaS income with scalable payments and advertising-oriented life sciences revenue.

🧠 Competitive Advantages & Market Positioning

Phreesia’s primary differentiators include an integrated, end-to-end patient intake platform, deep integration capabilities with leading EHR systems, and a large, growing installed base of healthcare clients. The company’s experience in navigating rigorous healthcare compliance regulations (such as HIPAA) positions it as a trusted partner in an industry wary of data security and privacy. The platform also leverages significant patient touchpoints, enabling a data-rich environment for process improvement, predictive analytics, and targeted patient engagement. This trove of data further enhances Phreesia’s value proposition to both providers—who seek actionable insights to boost operational efficiency—and to life sciences organizations interested in digital outreach within provider networks. Phreesia maintains high switching costs; migrating away from its platform can impose workflow disruption and retraining pains for large medical organizations. Its reputation, scale of integrations, and holistic product suite place it ahead of point-solution newcomers and less-specialized EHR-centric offerings. Nevertheless, the competitive environment remains dynamic, characterized by a mixture of legacy players, EHR vendors, and emerging startups.

🚀 Multi-Year Growth Drivers

Phreesia is positioned to benefit from several secular and industry-specific tailwinds: - **Healthcare Digitalization:** Continued adoption of health IT platforms as providers seek operational efficiencies, cost reductions, and regulatory compliance. - **Patient Consumerization:** Growing demand for digital, user-friendly patient experiences, including online intake, appointment scheduling, and digital payments. - **Expanding Addressable Market:** Acceleration of multi-specialty practices, ambulatory networks, and health systems deploying enterprise intake solutions. - **Data Monetization:** Increasing interest from life sciences and payers in digital patient engagement and data-driven clinical insights. - **Regulatory Mandates:** Ongoing regulatory changes requiring patient access, electronic reporting, and secure communication platforms. - **Product Upselling/Cross-Selling:** The stickiness of the platform opens cross-sell opportunities across payments, surveys, outcomes collection, and analytics. - **Tuck-in Acquisitions:** Occasional expansion through targeted acquisitions to add modules, enter new specialties, or enhance capabilities. Cumulatively, these factors underpin a long-term path for both revenue growth and margin expansion as operating leverage materializes with scale.

⚠ Risk Factors to Monitor

Investors should consider several risk vectors: - **Competitive Threats:** Larger EHR vendors or well-funded startups may invest aggressively to replicate or surpass Phreesia’s capabilities. - **Regulatory Environment:** Unexpected changes in healthcare privacy, reimbursement, or billing regulations could affect workflows, demand, or data monetization. - **Execution Risk:** Scaling complex healthcare SaaS requires continual investment in product, security, and support; missteps could impact retention. - **Client Concentration:** Dependence on key large provider networks could translate into revenue volatility if any major group switches platforms. - **Macroeconomic Factors:** Industry consolidation or budget constraints in healthcare could slow contract wins or up-sells. - **Cybersecurity and Data Privacy:** As a steward of sensitive data, a material breach could have outsized reputational and financial impacts.

📊 Valuation & Market View

Phreesia is typically valued as a high-growth healthcare SaaS company, with market participants focusing on its long-term recurring revenue profile and penetration of a large TAM (total addressable market). The company tends to trade at revenue multiples reflective of robust annualized growth, a "land-and-expand" customer dynamic, and the eventual path toward sustainable free cash flow margin expansion as investments in go-to-market mature. Key valuation debates center on the pace of revenue growth versus operating loss leverage, the sustainability of gross margin (given the blend of SaaS and payment transaction fees), and the premium placed on healthcare technology specialists relative to broader software or medtech sectors. Third-party channels (e.g., life sciences revenue) are often assigned higher-margin multiples, creating optionality within the sum-of-the-parts analysis.

🔍 Investment Takeaway

Phreesia stands out as a mission-critical healthcare technology platform addressing core administrative workflows and patient engagement for providers. Its diversified revenue streams, high retention rates, and embeddedness within the healthcare IT stack underpin structural advantages over niche competitors and EHR vendors seeking to bolt on intake solutions. The company’s secular growth outlook is driven by industry-wide digital adoption, increasing consumer expectations for patient experience, and growing demand for data-driven clinical and commercial insights. However, Phreesia operates within a competitive, heavily regulated landscape subject to rapid innovation cycles and evolving buyer preferences. Execution risks and sensitivity to changing provider or regulatory environments merit ongoing diligence. For investors able to underwrite a multi-year digital health wave, Phreesia represents an opportunity to participate in category leadership within a defensible, scalable healthcare SaaS segment—albeit with volatility typical of growth-stage healthtech disruptors.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

Management delivered strong Q4 profitability and cash conversion (Adj. EBITDA $29.4M; FCF $28.5M) driven by AccessOne/PAYMENTS, while highlighting AI as the engine for further margin gains. However, in the Q&A the “tough market” became tangible: FY2027 revenue guidance was cut by ~$35M–$39M ($510M–$520M vs prior $545M–$559M) due to reduced/variable pharma commitments within Network Solutions, concentrated in specific brands/therapeutic areas (notably vaccines and federal public-health agencies). Management explicitly held Adjusted EBITDA steady ($125M–$135M) despite the revenue downshift, implying cost/efficiency actions (including AI-enabled reduction in outsourced/manual work) are expected to offset the drop. Analyst pressure focused on why ProviderConnect doesn’t appear to cushion the guide (it was described as “very small” and “inconsequential” for this conversation) and what is structural vs temporary; management provided examples of therapeutic pullbacks but avoided attributing the change to MFN/Medicare drug price renegotiations. Overall tone is confident, but the underlying drivers show real near-term demand visibility risk.

AI IconGrowth Catalysts

  • Payment Solutions growth led by AccessOne acquisition (revenue up 16% YoY; excluding AccessOne revenue up 7%)
  • HCP marketing initiative: ProviderConnect launched early March 2026 as extension of PatientConnect
  • AI-driven internal automation to reduce outsourced resources and drive margin expansion

Business Development

  • AccessOne acquisition (closed in November; 80 AHSCs contributed via AccessOne in Q4)
  • ProviderConnect launch (early March 2026); positioned as privacy-preserving point-of-care media offering for provider marketers

AI IconFinancial Highlights

  • Q4 revenue: $127.1M, +16% YoY (Payment Solutions leading); excluding AccessOne: +7% YoY
  • Q4 Adjusted EBITDA: $29.4M vs $16.4M prior year; Adjusted EBITDA margin: 23%
  • Q4 AHSC: 4,658 total (+138 vs prior quarter); 80 AHSCs contributed through AccessOne
  • Q4 revenue per AHSC: $27,279, +8% YoY
  • Q4 operating cash flow: $33.7M (+$17.4M YoY); Q4 free cash flow: $28.5M (+$19.3M YoY)
  • FY 2026 milestones: crossed $100M Adjusted EBITDA, crossed $50M free cash flow; first positive GAAP net income as public company
  • FY 2027 revenue guidance cut: $510M–$520M vs prior $545M–$559M (range reduction of ~$35M–$39M)
  • FY 2027 Adjusted EBITDA guidance maintained: $125M–$135M despite lower revenue outlook
  • FY 2027 AHSC growth maintained: mid-single-digit percentage range
  • FY 2027 revenue per AHSC guide lowered to low single-digit percentage range (from low double-digit previously)

AI IconCapital Funding

  • 03/13/2026 refinancing: repaid bridge loan using $92.0M borrowings
  • New financing: $275.0M five-year senior secured revolving credit facility (Capital One), maturity 03/13/2031
  • Incremental detail: unused revolver capacity available for working capital, capex, permitted acquisitions, and general corporate purposes
  • Cash & cash equivalents: $73.8M as of 01/31/2026 vs $84.2M as of 01/31/2025

AI IconStrategy & Ops

  • AI adoption to reduce manual processes and initial efficiencies expected in outsourced resource utilization
  • Cost/action framing: management emphasized ongoing margin expansion efforts through efficiency gains; no line-item expense targets provided (R&D expected to be larger contributor to expense ratio improvement; S&M and G&A to improve but less)
  • Network Solutions forecasting variability management: guidance update explicitly assumes no additional revenue from potential future acquisitions through 01/31/2027

AI IconMarket Outlook

  • FY 2027 revenue: $510M–$520M
  • FY 2027 Adjusted EBITDA: $125M–$135M (held steady)
  • FY 2027 total revenue per AHSC: low single-digit percentage range (previously low double-digit)
  • FY 2027 AHSC growth: mid-single-digit percentage range
  • ProviderConnect contribution: explicitly characterized as “very small”/“inconsequential” to explain the guidance change

AI IconRisks & Headwinds

  • Network Solutions visibility deterioration: shorter visibility into certain pharmaceutical manufacturers’ spending commitments; more variability particularly in 2H
  • Change not broad-based; concentrated in specific brands and therapeutic areas
  • Examples cited: vaccines spending pulled back; public health growth via federal government agencies also pulled back
  • Regulatory/macro risk context: management acknowledged other issues impacting pharma budgeting; did not tie to price negotiations/MFN or Medicare high-volume drug price renegotiations (responded “not really what we are tying into”)
  • Communication risk: management expects year-over-year revenue cadence to imply low end of guide down a few points and high end about flat (no segment-level numeric breakdown provided in Q&A)

Sentiment: MIXED

Note: This summary was synthesized by AI from the PHR Q4 2026 (FY ended 01/31/2026; call dated 2026-03-30) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PHR)

© 2026 Stock Market Info — Phreesia, Inc. (PHR) Financial Profile